Health care funding decisions and real world benefits: reducing bias by matching untreated patients

14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials.  ...

Read more →

Advancing international collaboration on COVID-19 real world evidence and observational studies

4 June 2021 - Medicines regulators from around the world discussed the importance of global collaboration and information sharing in relation ...

Read more →

Roche Canada announces collaboration to improve access to personalised health care with real world evidence

28 May 2021 - BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate ...

Read more →

Leading real world data and analytics organisations form industry coalition to advance policies to support regulatory use of real world evidence

19 May 2021 - RWE Alliance Launched by Aetion, Flatiron Health, IQVIA, Syapse, and Tempus. ...

Read more →

Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?

15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...

Read more →

Do existing real world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal

28 April 2021 - Technological and computational advancements offer new tools for the collection and analysis of real world data.  ...

Read more →

NICE signs up to join the GetReal Institute

28 April 2021 -NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence ...

Read more →

ICER to use Aetion observational RWE to update value assessment of treatments for hereditary angioedema

12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost ...

Read more →

U.S. plans to use real world and trial data to determine when vaccines need to be updated

17 March 2021 - U.S. officials plan to use data gathered from people who have already been vaccinated against COVID-19 as ...

Read more →

Leveraging real world evidence in regulatory submissions of medical devices

16 March 2021 - Among the many ways that the U.S. FDA protects and promotes the public health is by ensuring ...

Read more →

COVID-19 vaccines - safety and effectiveness in older adults

10 March 2021 - Data on real-world use of COVID-19 vaccines approved in Australia provides reassurance about their safety in ...

Read more →

International regulators working together to enhance collaboration on COVID-19 observational research

8 February 2021 - In a dedicated COVID-19 workshop, convened under the umbrella of the International Coalition of Medicines Regulatory Authorities, ...

Read more →

Workshop on evaluating RWE from observational studies in regulatory decision-making

12 January 2021 - The FDA and the Duke-Margolis Center for Health Policy will hold a virtual workshop focused on ...

Read more →

STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies

12 January 2021 - In alignment with the International Council of Harmonization’s strategic goals, a public private consortium has developed a ...

Read more →

ICER Analytics launched to accelerate the real world application of ICER reports, helping payers, the life science industry, and health care policy makers move from insight to action

30 November 2020 - The Institute for Clinical and Economic Review today formally launched ICER Analytics, a new cloud-based platform that ...

Read more →